Athyrium Capital Management has agreed to a $50 million royalty financing deal with Esperion Therapeutics, acquiring royalty rights on Japan net sales of bempedoic acid products from Otsuka Pharmaceutical. The non-dilutive capital will support Esperion's acquisition of Corstasis Therapeutics, developer of Enbumyst™, the first FDA-approved intranasal loop diuretic. This marks Athyrium's second investment in Esperion within 16 months.

Esperion Therapeutics completed its acquisition of Corstasis Therapeutics, integrating Enbumyst (bumetanide nasal spray), the first FDA-approved nasal spray loop diuretic, into its cardiovascular portfolio. The acquisition is expected to drive portfolio expansion, leverage Esperion's existing commercial infrastructure, and support revenue growth in the treatment of edema associated with congestive heart failure and hepatic/renal disease.

Esperion Therapeutics has completed its acquisition of Corstasis Therapeutics, adding Enbumyst (bumetanide nasal spray) to its cardiovascular portfolio. Enbumyst is the first and only FDA-approved nasal spray loop diuretic for treating edema associated with congestive heart failure and hepatic/renal disease. Esperion plans to leverage its existing cardiovascular commercial infrastructure to drive adoption and revenue growth.

Esperion Therapeutics announced a definitive agreement to acquire Corstasis Therapeutics for $75 million upfront plus up to $180 million in milestone payments. The acquisition includes Enbumyst, the first FDA-approved nasal spray diuretic for congestive heart failure edema. Esperion shares fell 5.4% in premarket trading as the broader market declined. The company expects the deal to close in Q2 2026 and drive double-digit revenue growth.

Esperion announced a settlement agreement with Alkem Laboratories Ltd. to prevent the marketing of generic versions of NEXLETOL and NEXLIZET in the United States until April 19, 2040. This is the fifth ANDA filer to reach such an agreement with Esperion. Patent litigation against four remaining defendants (Aurobindo Pharma, MSN Pharmaceuticals, Renata Limited, and Sandoz Inc.) continues with uncertain outcomes.

Esperion announced that its partner Otsuka launched NEXLETOL in Japan, receiving a $90 million payment for the cardiovascular prevention drug's national health insurance price listing and market entry.

HLS Therapeutics received Health Canada approval to market NILEMDO® for reducing LDL-Cholesterol in Canadians at risk of cardiovascular disease, with commercial launch expected in Q2 2026.

Esperion announced the appointment of John Harlow as Chief Commercial Officer, bringing over two decades of pharmaceutical leadership experience to drive commercial strategies and global expansion of cardiovascular risk reduction therapies.

Esperion will present two research analyses at the AHA Scientific Sessions in New Orleans, focusing on bempedoic acid's impact on LDL cholesterol and cardiovascular events, including a monotherapy analysis and a study on venous thromboembolism.

Esperion Therapeutics plans to raise approximately $75 million through a public offering of 30 million shares at $2.50 per share, with underwriters having an option to purchase an additional 4.5 million shares.

Esperion Therapeutics plans to conduct an underwritten public offering of common stock, with Piper Sandler and Cantor Fitzgerald as joint book-running managers. The offering is subject to market conditions and will be made through a prospectus supplement.

Esperion has settled patent litigation with Dr. Reddy's Laboratories, agreeing that generic versions of NEXLETOL and NEXLIZET will not be marketed in the US before April 19, 2040.